TGFB1 and chronic kidney disease: We previously reported that an endogenous tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline that inhibited renal fibrosis via blockade of the profibrotic TGF-β signal transduction pathway significantly ameliorated the progression of renal dysfunction in a rat CKD model [19].